Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals has allotted 12,653 equity shares under ESOP. Consequently, the paid up equity share capital has increased 28,22,00,809 equity shares of Re. 1 each aggregating to Rs. 28,22,00,809/-. Powered by Capital Market - Live

The company will launch Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (mixed salts of a single entity Amphetamine product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg. Glenmark's product is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall Tablets (5 mg to 30 mg), marketed by Teva Women's Health, Inc. Distribution is scheduled to begin in May 2025. According to IQVIA, sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market achieved annual sales of approximately $421.7 million. Commenting on the launch, Marc Kikuchi, president with a focus on therapeutic areas of cardiometabolic, respiratory, dermatology and oncology Glenmark Pharmaceuticals is a research-led, global pharmaceutical company, having a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of cardiometabolic, respiratory, dermatology and oncology. The company reported a consolidated net profit of Rs 347.96 crore in Q3 FY25 as compared with net loss of Rs 351.37 crore in Q3 FY24. Net sales increased 34.2% YoY to Rs 3,301.90 crore in Q3 FY25. The counter declined 1.34% to settle at Rs 1,356.95 on Wednesday, 17 April 2025.Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg. Glenmark's Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets (Mixed Salts of a Single Entity Amphetamine Product), 5 mg, 10 mg, 15 mg, 20 mg and 30 mg is bioequivalent and therapeutically equivalent to the reference listed drug, Adderall'2 Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, of Teva Women's Health, Inc. and the company will begin distribution in May 2025. According to IQVIA sales data for the 12-month period ending February 2025, the Adderall' Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market achieved annual sales of approximately $421.7 million. Powered by Capital Market - Live

Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1371.95, down 0.32% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is up around 2.16% on the day, quoting at 22882.3. The Sensex is at 75328, up 2.01%.Glenmark Pharmaceuticals Ltd has lost around 3.54% in last one month.Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has increased around 0.27% in last one month and is currently quoting at 19976.3, up 2.51% on the day. The volume in the stock stood at 4.59 lakh shares today, compared to the daily average of 6.56 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 1376.9, up 0.02% on the day. Glenmark Pharmaceuticals Ltd jumped 30.44% in last one year as compared to a 1.61% rally in NIFTY and a 9% spurt in the Nifty Pharma index.The PE of the stock is 16.86 based on TTM earnings ending December 24.Powered by Capital Market - Live

Glenmark Pharmaceuticals has appointed Anurag Mantri as President (Senior Management Personnel) with effect from 07 April 2025. Further, V.S. Mani, Executive Director & Global Chief Financial Officer of the Company has decided to step down with effect from 26 May 2025. The candidature of Anurag Mantri to the office of Executive Director & Global Chief Financial Officer will be put up before Audit Committee, Nomination & Remuneration Committee and Board of the Company in the ensuing committee meetings/Board meeting for approval and once approved, he will then be appointed as Executive Director and Global Chief Financial Officer. Powered by Capital Market - Live

Vancomycin injection is used alone or in combination with other medications to treat certain serious infections, such as endocarditis (infection of the heart lining and valves), peritonitis (inflammation of the lining of the abdomen), and infections of the lungs, skin, blood, and bones. It belongs to a class of medications called glycopeptide antibiotics and works by killing the bacteria that cause infections. Glenmark's Vancomycin Hydrochloride for Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, marketed by Mylan Laboratories. According to IQVIA' sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP market achieved annual sales of approximately $39.3 million. Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024. The scrip shed 0.58% to Rs 1,531.05 on the BSE Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial). Glenmark's Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial of Mylan Laboratories, NDA 209481. According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market2 achieved annual sales of approximately $39.3 million. Powered by Capital Market - Live

The product has been determined to be bioequivalent to Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), developed by Alcon Laboratories, Inc. With this approval, Glenmark Therapeutics Inc., USA, will distribute the product in the US market, further expanding the company's ophthalmic portfolio. Olopatadine ophthalmic (eye) drops are used to treat itching of the eye caused by a condition known as allergic conjunctivitis (pink eye). This medicine is also used to treat eye itching or redness caused by pollen, ragweed, grass, animal hair, or dander. According to Nielsen syndicated data for the 52-week period ending 22 February 2025, the Pataday Once Daily Relief Ophthalmic Solution, 0.2% (OTC), achieved annual sales of approximately $50.7 million. Commenting on the launch, Marc Kikuchi, president & business head of North America, said, 'We are pleased to continue expanding our OTC ophthalmic portfolio. The addition of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.2%, highlights our commitment to meeting market needs and providing quality over-the-counter solutions for our customers.' Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024.Powered by Capital Market - Live

Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). These medications are designed to improve glycemic control in adults with T2DM while also reducing cardiovascular outcomes in T2DM patients with CV risk.  Empagliflozin is a globally established treatment for HF, T2DM and T2DM with established cardiovascular disease (CVD), offering multiple benefits like cardiovascular and renal safety. The EMPA-REG clinical trial demonstrated a 14% reduction in major cardiovascular events, positioning Empagliflozin as a significant advancement in T2DM patients with high CV risks.Powered by Capital Market - Live

The drug will be marketed under the brand name Glempa (Empagliflozin 10/25 mg), along with its fixed-dose combinations (FDCs)'Glempa-L (Empagliflozin 10/25 mg + Linagliptin 5 mg) and Glempa-M (Empagliflozin 12.5 mg + Metformin 500/1000 mg). Empagliflozin is a globally established treatment for heart failure and diabetes, offering multiple benefits, including cardiovascular and renal safety. Alok Malik, President and Head of India Formulations Business, Glenmark Pharmaceuticals, said, 'Glenmark has a strong legacy of introducing innovative and accessible treatments for cardiometabolic care in India. The launch of the Glempa range reinforces this commitment by providing a comprehensive and affordable solution that empowers healthcare professionals and patients to manage T2DM with established CVD more effectively.' Glenmark Pharmaceuticals is a global innovation-driven pharmaceutical company with a presence across specialty, generics, and OTC businesses. The company has 11 world-class manufacturing facilities spread across 4 continents and operations in over 80 countries. On a consolidated basis, the company reported a net profit of Rs 348 crore in Q3 FY25 compared with a net loss of Rs 449.6 crore in Q3 FY24. Revenue from operations surged 35.1% YoY to Rs 3,387.6 crore in the quarter ended 31 December 2024. The scrip fell 1.38% to currently trade at Rs 1,381.15 on the BSE.Powered by Capital Market - Live